Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Up 18.8% in March

Aptevo Therapeutics Inc. (NASDAQ:APVO) saw a significant growth in short interest in March. As of March 31st, there was short interest totaling 133,103 shares, a growth of 18.8% from the March 15th total of 112,000 shares. Currently, 11.3% of the shares of the stock are short sold. Based on an average trading volume of 53,580 shares, the short-interest ratio is currently 2.5 days.

Aptevo Therapeutics Stock Performance

APVO stock opened at $5.28 on Friday. The firm has a fifty day moving average price of $5.50 and a 200 day moving average price of $14.44. Aptevo Therapeutics has a fifty-two week low of $3.80 and a fifty-two week high of $486.00. The firm has a market cap of $6.23 million, a PE ratio of 0.00 and a beta of 1.50.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Friday, March 27th. The biotechnology company reported $118.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($8.10) by $126.33. On average, equities analysts predict that Aptevo Therapeutics will post -15.84 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC purchased a new position in Aptevo Therapeutics Inc. (NASDAQ:APVO) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent SEC filing. 8.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have commented on APVO. Weiss Ratings reiterated a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Monday, December 29th. Wall Street Zen raised Aptevo Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Aptevo Therapeutics has an average rating of “Hold”.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.